COMBINATION OF LOTEPREDNOLETABONATE AND DFHO FOR THE TREATMENT OF RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND COPD

摘要

The invention relates to a novel combination of a glucocorticoid, especially loteprednol, and at least one phospho-diesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorbenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or separate administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD).